Blau Farmaceutica S.A. is a pharmaceutical industry leader in the institutional segment and a pioneer in biotechnology among Brazilian companies. They have their own portfolio of high-complexity medications, focusing on various industry sectors such as immunology, hematology, oncology, nephrology, infectology, and anesthesiology. The company has a continental presence, operating in seven countries in South America (Argentina, Brazil, Chile, Colombia, Ecuador, Peru, Uruguay) and the United States. They have a modern pharmaceutical industrial complex consisting of five plants in Brazil, with high production capacity and cutting-edge technology. In 2023, with the acquisition of Laboratório Bergamo, Blau Farmaceutica S.A. becomes part of the Blau Group, with an expanded portfolio in the oncology and hematology field and increased production capacity in the country. Blau's portfolio includes their own brand of high-complexity biological and synthetic products, serving the main therapeutic areas in the hospital products market, including infectology, oncology, hematology, nephrology, and specialties. These products have significant potential for consumption growth.
Headquarters
Rodovia Raposo Tavares, Km 30, 5, N. 2.833, Unidade I, Predios 100/110, Barro Branco
Cotia; Sao Paulo;
Postal Code: 6705030
Contact Details: Purchase the Blau Farmaceutica S.A. report to view the information.
Website: http://ri.blau.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service